Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer

Astellas and Pfizer reported positive topline Phase 3 EV-304 (KEYNOTE-B15) results showing PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) met the primary endpoint with clinically meaningful and statistically significant improvements in event-free survival and also achieved a key secondary endpoint of improved overall survival versus standard cisplatin-based chemotherapy in muscle-invasive bladder cancer. The combination also produced a statistically significant improvement in pathologic complete response and had a safety profile consistent with known characteristics; the companies plan to present the data at a medical meeting and discuss filings with global regulators, supporting the potential establishment of a new platinum-free perioperative standard of care.

Analysis

Market structure: The clear near-term winners are Astellas (ALPMY / 4503.T) and any PADCEV commercial partners, with an ancillary boost to partners named in press coverage (Pfizer/PFE) and to Merck (MRK) indirectly because Keytruda is required in the combo; losers are incumbent cisplatin chemotherapy suppliers and generic chemo manufacturers (e.g., TEVA) and hospital pathways that rely on platinum-based perioperative regimens. If PADCEV+Keytruda achieves 30–50% penetration of cisplatin-eligible MIBC within 2–4 years, it can reallocate high-margin ADC and immunotherapy revenue away from lower-margin chemo, improving pricing power for ADC players.

Risk assessment: Tail risks include regulatory rejection or a surprise safety signal (probability ~10–20%), manufacturing constraints for ADC supply (15% chance of rollout delays), and commercial/label complexity given Keytruda’s ownership by MRK (contract/IP friction risk ~10%). Immediate impact is likely a multi-day positive re-rate in PFE/ALPMY, short-term (30–180 days) driven by regulatory filings and presentations, and long-term (12–36 months) dependent on payer coverage and manufacturing scale-up.

Trade implications: Favor a modest long bias: establish 2–3% long position in PFE and 1–2% long in ALPMY (or 4503.T) to capture upside into regulatory discussion windows (next 30–90 days) while hedging with inexpensive 6–12 month protective puts (collar). Consider pair: long ALPMY (2%) / short TEVA (1–2%) to express ADC vs. generic chemo spread; for options, sell short-dated post-event call premium if IV spikes, or buy 9–12 month call spreads on ALPMY to limit cost.

Contrarian angles: The market may be over-pricing immediate commercial impact—cisplatin-eligible MIBC is a limited population, so full revenue ramp likely takes 12–36 months and faces payer pushback. Also, the article’s naming (Pfizer vs. Merck/Keytruda) highlights potential misunderstanding of commercial economics; confirm partnership/revenue shares before levering positions. Historical precedent (PD-1 adjuvant rollouts) shows strong trials do not guarantee fast reimbursement—price and access negotiations can compress near-term upside.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in PFE (Pfizer) within 7 trading days to capture positive rerating ahead of regulatory discussions; pair this with a 6–12 month protective put (cost <1% of position) to cap downside from trial re-interpretation or safety headlines.
• Buy a 1–2% position in Astellas via ALPMY (or 4503.T) as a targeted oncology-growth bet, funded by a 1% reduction in generic oncology exposure (e.g., reduce TEVA by 1–2%); use 9–12 month call spreads on ALPMY to limit premium spend if available.
• Enter a pair trade: long ALPMY (2%) / short TEVA (1–2%) to express ADC adoption versus generic cisplatin suppliers; re-evaluate after the medical meeting presentation (within 30–60 days) and close or trim if payer commentary is unfavorable.
• If implied volatility in PFE/ALPMY spikes >40% post-announcement, sell short-dated (30–60 day) call spreads equal to ~25–50% of your long exposure to harvest IV contraction; cap max notional to 1–2% of portfolio risk.
• Do not increase exposure beyond stated sizes until: (a) regulatory filing timelines are public (expect 30–90 days), (b) manufacturing capacity commentary is disclosed, or (c) a favorable HTA/payer decision appears (likely 6–18 months); otherwise keep positions hedged.